SDS Biotech K.K. reported earnings results for the second quarter of 2021. Net sales were JPY 5.012 billion, an increase of JPY 175 million, or 3.6%, year on year. Operating income was JPY 355 million, an increase of JPY 291 million from the same period of the previous fiscal year. Ordinary income was JPY 950 million, an increase of JPY 500 million or 111.4% year on year, due to the recording of JPY 583 million in dividend income from companies invested in China. Quarterly net income was JPY 739 million, an increase of JPY 245 million, or 49.8%, compared with the same period of the previous fiscal year.